Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment-free remission in CML

Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Key clinical point: Second-line nilotinib led to treatment-free remission in CML patients who achieved sustained molecular response.

Major finding: In total, 58% of patients who switched to nilotinib experienced treatment-free remission at 48 weeks.

Study details: A single-group, open-label phase 2 study.

Disclosures: Novartis Pharmaceuticals funded the study. The researchers reported financial ties to Novartis and other pharmaceutical companies.

Source: Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Read the article.

Citation:

Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

This Week's Must Reads

RNA expression offers potential biomarker in hemophilia A, Niloofar N et al. Hematology. 2019;24(1):255-62

Caplacizumab speeds platelet normalization, Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311

Remote area of Canada provides pool for genetic research, Scully M-F et al. Transfus Apher Sci. 2018 Dec;57(6):713-6

Can web tools replace pharmacokinetic analysis in hemophilia A?, Nagao A et al. Thromb Res. 2019 Jan;173:79-84

BSH issues recommendations for glucocorticoid use in ITP, Hill QA et al. Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15735

Must Reads in CML

Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Bosulif Approved to Treat Newly-Diagnosed Ph+ CML, Avillion news release; 2017 Dec 19

Sprycel Approved for Children with Ph+ CML, FDA news release; 2017 Nov 9

Be Sure to Consider This When Selecting TKIs, Clin Lymphoma Myeloma Leuk; ePub 2017 Jun 16; Coutinho, et al

FDA Approves Iclusig for Certain Types of CML, ALL, Ariad news release; 2016 Nov 29